Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EZHiSWITCH
2024-519788-16-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valemetostat in Nonhematologic neoplasms, endometrial cancer (EC), carcinoma and 4 more, sponsored by Gustave Roussy. Primary endpoint: Overall Response Rate at 24 weeks. Planned start Dec 2025; status: authorised.
02
Drugs
valemetostat
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)carcinomaclear cell renal cell carcinoma (ccRCC)mesothelioma
Beyond the preview
Go deeper on 2024-519788-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519788-16-00.